Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on Tuesday announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies to manufacture ...

New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs in the ...

CEO Leonard Schleifer reported "double-digit net sales growth for 3 of our leading products," highlighting a 26% increase in Dupixent, 24% for Libtayo at constant exchange rates, and a 10% increase ...

(Reuters) -Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth, potentially doubling its U.S. manufacturing ...

Switzerland-based Roche said it will spend $50B in the U.S. over the next five years and create 12,000 jobs. The investment will fund research and development facilities as well as new manufacturing ...

Recently, Regeneron Pharmaceuticals saw a wave of analyst upgrades from major banks such as Bank of America Securities and ...

FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced a 10-year manufacturing ...

Regeneron Pharmaceuticals signed a new manufacturing-and-supply agreement with Fujifilm Diosynth Biotechnologies to double its large-scale manufacturing in the U.S. Regeneron's new investment with ...

ALBANY, N.Y. (AP) — Regeneron Pharmaceuticals Inc. plans a $70 million expansion that will add 300 biotech jobs to its upstate New York operation. Gov. Andrew Cuomo says the Tarrytown-based company is ...

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...